Owada T - Search Results

1

Intensive immunosuppressive therapy for endogenous lipoid pneumonia associated with rheumatoid arthritis.

Morita H, Arai S, Kurasawa K, Okada H, Tanaka A, Yamazaki R, Owada T, Maezawa R. Morita H, et al. Among authors: owada t. Mod Rheumatol. 2018 Nov;28(6):1044-1048. doi: 10.1080/14397595.2016.1193270. Epub 2016 Jun 20. Mod Rheumatol. 2018. PMID: 27321430

2

Autoantibodies against platelet-derived growth factor receptor alpha in patients with systemic lupus erythematosus.

Kurasawa K, Arai S, Owada T, Maezawa R, Kumano K, Fukuda T. Kurasawa K, et al. Among authors: owada t. Mod Rheumatol. 2010 Oct;20(5):458-65. doi: 10.1007/s10165-010-0310-x. Epub 2010 May 21. Mod Rheumatol. 2010. PMID: 20490598

3

Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases.

Maezawa R, Kurasawa K, Arai S, Okada H, Owada T, Fukuda T. Maezawa R, et al. Among authors: owada t. Mod Rheumatol. 2013 Jan;23(1):62-70. doi: 10.1007/s10165-012-0625-x. Epub 2012 Mar 31. Mod Rheumatol. 2013. PMID: 22466117

4

Detection of inflammatory lesions by f-18 fluorodeoxyglucose positron emission tomography in patients with polymyositis and dermatomyositis.

Owada T, Maezawa R, Kurasawa K, Okada H, Arai S, Fukuda T. Owada T, et al. J Rheumatol. 2012 Aug;39(8):1659-65. doi: 10.3899/jrheum.111597. Epub 2012 Jul 1. J Rheumatol. 2012. PMID: 22753657

5

Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis.

Arai S, Kurasawa K, Maezawa R, Owada T, Okada H, Fukuda T. Arai S, et al. Among authors: owada t. Mod Rheumatol. 2013 Sep;23(5):872-83. doi: 10.1007/s10165-012-0756-0. Epub 2012 Sep 17. Mod Rheumatol. 2013. PMID: 22983659

6

Clinical features of organizing pneumonia associated with rheumatoid arthritis.

Okada H, Kurasawa K, Yamazaki R, Tanaka A, Arai S, Owada T, Maezawa R, Ishii Y. Okada H, et al. Among authors: owada t. Mod Rheumatol. 2016 Nov;26(6):863-868. doi: 10.3109/14397595.2016.1153217. Epub 2016 Apr 4. Mod Rheumatol. 2016. PMID: 26872745

7

Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.

Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, Arima M, Maezawa R. Kurasawa K, et al. Among authors: owada t. Rheumatology (Oxford). 2018 Dec 1;57(12):2114-2119. doi: 10.1093/rheumatology/key188. Rheumatology (Oxford). 2018. PMID: 30060040

8

Systemic lupus erythematosus complicating autoimmune pulmonary alveolar proteinosis that was worsened by immunosuppressive therapy.

Nagasawa J, Kurasawa K, Maezawa R, Owada T, Hanaoka R, Fukuda T. Nagasawa J, et al. Among authors: owada t. Lupus. 2013 Sep;22(10):1060-3. doi: 10.1177/0961203313498798. Epub 2013 Jul 25. Lupus. 2013. PMID: 23886640

9

Changing patterns of pulmonary abnormalities in rheumatoid arthritis.

Tanaka A, Kurasawa K, Soda S, Takamura Y, Miyao T, Hasegawa A, Hiyama T, Yamazaki R, Arai S, Owada T, Arima M, Arakawa H, Maezawa R. Tanaka A, et al. Among authors: owada t. Respir Investig. 2023 Jan;61(1):27-39. doi: 10.1016/j.resinv.2022.09.002. Epub 2022 Oct 4. Respir Investig. 2023. PMID: 36207238

10

Dr. Owada, et al, reply.

Owada T, Maezawa R, Kurasawa K. Owada T, et al. J Rheumatol. 2013 Jan;40(1):92. doi: 10.3899/jrheum.121243. J Rheumatol. 2013. PMID: 23401877 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

121 results

Search Page